Assessing the effectiveness of biologics in biologic-naïve patients with isolated small bowel Crohn's disease by double-balloon endoscopy. (PubMed, Expert Opin Biol Ther) - Sep 18, 2026 - "This single‑center retrospective study included biologic‑naïve isolated SB‑CD patients who initiated infliximab (IFX) or ustekinumab (UST) between 2020 and 2025. Among biologic-naïve patients with isolated SB-CD, the overall ER rate after biologic treatment was 35.5%. IFX and UST showed comparable effectiveness in achieving ER."
Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease
|
|
Jing Hu; Juan Wu; Linlin Zhou; Peipei Zhang; Qiao Mei; Qiuyuan Liu; Wei Han; Yuanyuan Fang; Yumei Wu
|